Literature DB >> 11246166

Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain.

S Sweitzer1, D Martin, J A DeLeo.   

Abstract

The expression of interleukin-1beta and tumor necrosis factor has previously been shown to be up-regulated in the spinal cord of several rat mononeuropathy models. This present study was undertaken to determine whether blocking the action of central interleukin-1beta and tumor necrosis factor attenuates mechanical allodynia in a gender-specific manner in a rodent L5 spinal nerve transection model of neuropathic pain, and whether this inhibition occurs via down-regulation of the central cytokine cascade or blockade of glial activation. Interleukin-1 receptor antagonist or soluble tumor necrosis factor receptor was administered intrathecally via lumbar puncture to male Holtzman rats in a preventative pain strategy, in which therapy was initiated 1h prior to surgery. Administration of soluble tumor necrosis factor receptor attenuated mechanical allodynia, while interleukin-1 receptor antagonist alone was unable to decrease allodynia. Interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor, administered to both male and female rats in a preventative pain strategy, significantly reduced mechanical allodynia in a dose-dependent manner (P<0.01). The magnitude of attenuation in allodynia was similar in both males and females. Immunohistochemistry on L5 spinal cord revealed similar astrocytic and microglial activation regardless of treatment. At days 3 and 7 post-transection, animals receiving daily interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibited significantly less interleukin-6, but not interleukin-1beta, in the L5 spinal cord compared to vehicle-treated animals. In an existing pain paradigm, in which treatment was initiated on day 7 post-transection, interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor attenuated mechanical allodynia (P<0.05) in male rats. These findings further support a role for central interleukin-1beta and tumor necrosis factor in the development and maintenance of neuropathic pain through induction of a proinflammatory cytokine cascade.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246166     DOI: 10.1016/s0306-4522(00)00574-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  95 in total

Review 1.  Astrocyte-neuron communication: functional consequences.

Authors:  Sarrah Ben Achour; Olivier Pascual
Journal:  Neurochem Res       Date:  2012-06-06       Impact factor: 3.996

2.  Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury.

Authors:  Darryl Lau; Steven E Harte; Thomas J Morrow; Shiyong Wang; Marina Mata; David J Fink
Journal:  Neurorehabil Neural Repair       Date:  2012-05-15       Impact factor: 3.919

3.  Expression of IL-1beta in supraspinal brain regions in rats with neuropathic pain.

Authors:  A Vania Apkarian; Simona Lavarello; Anke Randolf; Hector H Berra; Dante R Chialvo; Hugo O Besedovsky; Adriana del Rey
Journal:  Neurosci Lett       Date:  2006-09-14       Impact factor: 3.046

4.  Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha.

Authors:  Xiaochun Jin; Robert W Gereau
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

Review 5.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

6.  Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway.

Authors:  Ru-Rong Ji; Yasuhiko Kawasaki; Zhi-Ye Zhuang; Yeong-Ray Wen; Isabelle Decosterd
Journal:  Neuron Glia Biol       Date:  2006-11

7.  Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain.

Authors:  Ji Zhang; Xiang Qun Shi; Stefania Echeverry; Jeffrey S Mogil; Yves De Koninck; Serge Rivest
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

8.  Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).

Authors:  Mark R Hutchinson; Yingning Zhang; Kimberley Brown; Benjamen D Coats; Mitesh Shridhar; Paige W Sholar; Sonica J Patel; Nicole Y Crysdale; Jacqueline A Harrison; Steven F Maier; Kenner C Rice; Linda R Watkins
Journal:  Eur J Neurosci       Date:  2008-07       Impact factor: 3.386

9.  Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury.

Authors:  G J Norman; K Karelina; N Zhang; J C Walton; J S Morris; A C Devries
Journal:  Mol Psychiatry       Date:  2009-09-22       Impact factor: 15.992

10.  Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats.

Authors:  Erin D Milligan; Carin Twining; Marucia Chacur; Joseph Biedenkapp; Kevin O'Connor; Stephen Poole; Kevin Tracey; David Martin; Steven F Maier; Linda R Watkins
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.